Clinical efficacy of leukofiltration on cardiopulmonary bypass related inflammatory response: Fact or Foe?

Basit Öğe Kaydı
dc.contributor.authorKılıç, Dilek
dc.contributor.authorGünaydın, Serdar
dc.contributor.authorKısa, Üçler
dc.contributor.authorSari, Tamer
dc.contributor.authorDeveci, Özcan
dc.contributor.authorZorlutuna, Yaman
dc.date.accessioned2020-06-25T17:48:24Z
dc.date.available2020-06-25T17:48:24Z
dc.date.issued2009
dc.departmentKırıkkale Üniversitesi
dc.descriptionKISA, Ucler/0000-0002-8131-6810
dc.description.abstractThe powerful precept of preoperative risk assessment has been applied to compare the efficacy of leukofiltration techniques for high-risk cohorts with the documentation of broad indicators of systemic inflammation. Forty high risk patients were prospectively assigned to four perfusion protocols; the first group (n=10): Polyethyleneoxide (PEO) based heparin bonded extracorporeal circuits (ECC) + Continuous Leukocyte filtration; the second group (n=10): uncoated ECC + leukofiltration; the third group (n=10): PEO based heparin bonded ECC without leukofiltration; and control (n=10). Blood samples were obtained at the following intervals: Baseline (T1), on cardiopulmonary bypass (CPB) (T2), Cross clamp (T3), off CPB (T4), Intensive care unit-24 h (ICU24) (T5), ICU48 (T6). Tumor Necrosis Factor-alpha levels were significantly lower in Group 1 at T3, T4 (p < 0.05) vs. control. Procalcitonin levels were significantly lower in Group 1 at T5, T6 (p < 0.05) vs. control. Creatinine kinase-MB levels in coronary sinus blood demonstrated well preserved myocardium in filtered+coated (Group1) and coated groups (Group3) (p < 0.05). Matrix metallopeptidase- 9 and D-Dimer levels in filtered+coated group were significantly lower at T5 and T6 vs. control (p < 0.05). Leukocyte filtration on coated surfaces alleviated systemic inflammatory response with a better clinical outcome in high risk patients.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1007/s00011-008-7244-1
dc.identifier.endpage297en_US
dc.identifier.issn1023-3830
dc.identifier.issn1420-908X
dc.identifier.issue6en_US
dc.identifier.pmid19266265
dc.identifier.scopus2-s2.0-67649532294
dc.identifier.scopusqualityQ1
dc.identifier.startpage292en_US
dc.identifier.urihttps://doi.org/10.1007/s00011-008-7244-1
dc.identifier.urihttps://hdl.handle.net/20.500.12587/4437
dc.identifier.volume58en_US
dc.identifier.wosWOS:000266240600002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Basel Agen_US
dc.relation.ispartofInflammation Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCardiopulmonary bypassen_US
dc.subjectCoated materialsen_US
dc.subjectBiocompatibleen_US
dc.subjectLeukapheresisen_US
dc.subjectReperfusion injuryen_US
dc.subjectLeukocyte Filtrationen_US
dc.subjectSurface Modifying Additivesen_US
dc.titleClinical efficacy of leukofiltration on cardiopulmonary bypass related inflammatory response: Fact or Foe?en_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Clinical efficacy of leukofiltration on cardiopulmonary bypass related inflammatory response Fact or Foe.pdf
Boyut:
424.8 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu